More and more doctors advising therapy as it promises better recovery in mild Covid cases
The treatment, called REGN-COV2, "reduces the risk of death when given to patients hospitalised with severe COVID-19 who have not mounted a natural antibody response of their own," researchers said.
Akanksha Chawala, a critical care pulmonologist at Apollo hospital in Delhi, said she had used the therapy in just two patients but the results had been extraordinary.
The two patients -- Suresh Kumar Trehan (65) and Sunirmal Ghatak (70) -- were administered with the therapy on June 1, said BLK-MAX Super Speciality Hospital.
The antibodies act against the spike protein of the Coronavirus (which attaches to human cells) and prevents organ damage.
Both of them had oxygen saturation level above 95 per cent and came to the hospital within three days of developing COVID-19 symptoms.
The decision to administer the antibody cocktail was taken by a board of doctors led by Director (Medical Services) of Apollo Hospitals Dr Ashish Chandra.
The patient responded well to the infusion of the antibody cocktail and went home after an hour of observation, hospital authorities said.
The MRP for the multi dose pack (each pack can treat two patients) is Rs 1,19,500 and the drug will be available through leading hospitals and COVID treatment centers.